Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profil
Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
04:30pm, Wednesday, 21'st May 2025
DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcar
Jazz Pharmaceuticals: One Step Forward, One Back
04:58am, Wednesday, 21'st May 2025
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compe
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
10:22am, Tuesday, 13'th May 2025
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
12:55pm, Wednesday, 07'th May 2025
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
11:06pm, Tuesday, 06'th May 2025
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
07:30pm, Tuesday, 06'th May 2025
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street est
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
06:20pm, Tuesday, 06'th May 2025
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago.
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
04:05pm, Tuesday, 06'th May 2025
– Total revenues of $898 million in 1Q25 –– Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca ® in 1L ES-
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
10:46am, Monday, 05'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
04:15pm, Wednesday, 30'th Apr 2025
DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
08:20am, Wednesday, 30'th Apr 2025
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 29'th Apr 2025
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
